Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

GSK 1,350.65 -4.85 (-0.36%)
price chart
Glaxo to Begin Hostile Offer for Human Genome Sciences
GlaxoSmithKline Plc will begin a hostile $2.6 billion tender offer this week for Human Genome Sciences Inc. after the U.S. company, its partner on the Benlysta drug for lupus, rebuffed a takeover approach.
Glaxo Diabetes Drug Data Revealed Amid Hostile Takeover
GlaxoSmithKline Plc will reveal detailed results today on an experimental treatment for diabetes that's part of the reason for a $2.6 billion hostile takeover bid for Human Genome Sciences Inc., its partner on the drug.
Glaxo's Stiefel Unit Loses $1.5 Million Verdict on Buybacks
Stiefel Laboratories lost a $1.5 million jury verdict to a former employee who claimed the company bought back his stock at artificially low prices before its acquisition in 2009 by GlaxoSmithKline Plc. Timothy Finnerty won the judgment on May 16 in ...
GlaxoSmithKline Launches Hostile Takeover Bid for Human Genome Sciences
GlaxoSmithKline Plc (NYSE: GSK), Britain's biggest drugmaker, will mount a $2.6 billion hostile takeover bid for Human Genome Sciences Inc. (NASDAQ: HGSI), the company announced Wednesday.
Human Genome in Talks With Potential Suitors
Human Genome Sciences Inc. said it's in talks with “major” pharmaceutical and biotechnology companies about a potential transaction and adopted measures to avoid a hostile takeover by GlaxoSmithKline Plc. Human Genome entered into confidentiality ...
GSK Says La. Can't Use Outside Attys In $12B Avandia Suit
Law360, New York (May 31, 2012, 4:30 PM ET) -- GlaxoSmithKline PLC urged a Louisiana state court on Thursday to bar the state's attorney general from using private attorneys to pursue a $12 billion Medicaid fraud suit over the safety risks of diabetes ...
Glaxo Scientist, Surgeon Targeting Historic British Hockey Gold
MacLeod, 27, also worked for GlaxoSmithKline Plc, the U.K.'s biggest drugmaker, as a sports scientist on its Lucozade energy drink.
GSK addresses Human Genome poison pill
by Laura Board | Published May 23, 2012 at 11:04 AM GlaxoSmithKline plc Wednesday, May 23, tweaked the terms of its hostile $2.59 billion offer for Human Genome Sciences Inc. to address a poison pill mechanism its target put in place last week.
GSK requests board to drop poison pill, blocking takeover of HGS
Glaxo growth plan
Calcutta, May 14: GlaxoSmithKline Consumer Healthcare Ltd (GSKCH) - an associate of GlaxoSmithKline plc - is planning to introduce some of its global oral healthcare, nutrition and high-protein products in India.
GSK, Valeant Dodge Sham Patent Suit Claims In Wellbutrin Row
Law360, New York (May 11, 2012, 4:56 PM ET) -- A Pennsylvania federal judge on Friday granted a move by GlaxoSmithKline PLC and Valeant Pharmaceuticals International to toss claims brought by purchasers of depression medication Wellbutrin XL in an ...